These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25336916)

  • 1. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
    Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
    Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.
    Kang WY; Lee HW; Gwon MR; Cho S; Shim WS; Lee KT; Yang DH; Seong SJ; Yoon YR
    Drug Des Devel Ther; 2020; 14():2101-2111. PubMed ID: 32546973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects.
    Kang WY; Seong SJ; Ohk B; Gwon MR; Kim BK; Cho S; Shim WS; Lee KT; Kim EH; Yang DH; Lee HW; Yoon YR
    Drug Des Devel Ther; 2018; 12():3607-3615. PubMed ID: 30464392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets.
    Hwang JG; Yu KS; Lee S
    Drug Des Devel Ther; 2020; 14():1953-1961. PubMed ID: 32546962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan.
    Kim CO; Lee HW; Oh ES; Seong SJ; Kim DY; Lee J; Ahn SH; Yoon YR; Cho CM; Park MS
    J Cardiovasc Pharmacol; 2013 Dec; 62(6):524-9. PubMed ID: 24084213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.
    Lee J; Rhee SJ; Lee S; Yu KS
    Drug Des Devel Ther; 2018; 12():787-794. PubMed ID: 29670335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.
    Yi S; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):682-9. PubMed ID: 21394036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects.
    Oh M; Ghim JL; Park SE; Kim EY; Shin JG
    Drug Des Devel Ther; 2018; 12():1157-1164. PubMed ID: 29780236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan.
    Gu N; Cho JY; Shin KH; Jang IJ; Rhee MY
    Drug Des Devel Ther; 2016; 10():1525-31. PubMed ID: 27143858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects.
    Ghim JL; Paik SH; Hasanuzzaman M; Chi YH; Choi HK; Kim DH; Shin JG
    J Clin Pharmacol; 2016 May; 56(5):576-80. PubMed ID: 26272450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers.
    Choi Y; Lee S; Jang IJ; Yu KS
    Drug Des Devel Ther; 2018; 12():2301-2309. PubMed ID: 30087555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of age on the pharmacokinetics of fimasartan (BR-A-657).
    Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Cho JY; Yu KS; Yoon YR
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1337-44. PubMed ID: 21950382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
    Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
    Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
    Jeon H; Lim KS; Shin KH; Kim J; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):84-91. PubMed ID: 21934629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.
    Kim JW; Yi S; Kim TE; Lim KS; Yoon SH; Cho JY; Lee MG; Song IS; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2013 Jan; 53(1):75-81. PubMed ID: 23400746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers.
    Kang WY; Kim EH; Seong SJ; Gwon MR; Yang DH; Kim HJ; Lim MS; Lee HW; Yoon YR
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):992-1003. PubMed ID: 27668695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives.
    Angeli F; Verdecchia P; Trapasso M; Pane M; Signorotti S; Reboldi G
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):533-541. PubMed ID: 29676941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic model of fimasartan applied to predict the influence of a high fat diet on its blood pressure-lowering effect in healthy subjects.
    Lee J; Han S; Jeon S; Hong T; Yim DS
    Eur J Clin Pharmacol; 2013 Jan; 69(1):11-20. PubMed ID: 22660441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats.
    Kim TH; Shin S; Bashir M; Chi YH; Paik SH; Lee JH; Choi HJ; Choi JH; Yoo SD; Bulitta JB; Ma E; Joo SH; Shin BS
    Xenobiotica; 2014 Oct; 44(10):913-25. PubMed ID: 24786684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.